Biohackers have been injecting it for years. In September 2025, the FDA made it official — and the implications go well beyond the rare disease it was approved for.
“The powerhouse of the cell.” You’ve heard it a thousand times. It’s the one biology fact everyone remembers, usually as a meme. But buried under the joke is something that matters enormously for performance, longevity, and how well you age: mitochondria don’t just produce energy. They regulate cellular stress responses, control inflammation signaling, manage calcium, and determine when a cell lives or dies. When they break down — and they break down with age, with overtraining, with metabolic disease — everything downstream suffers.
For decades, researchers knew this and could do almost nothing about it pharmacologically. You could take CoQ10, you could exercise, you could eat well. Nothing actually targeted the inner mitochondrial machinery.
SS-31 changed that. And in September 2025, the FDA made it the first mitochondria-targeted therapeutic ever approved.
What Is SS-31?
SS-31 — also called elamipretide, Bendavia, MTP-131, and now marketed as FORZINITY — is a synthetic tetrapeptide: a chain of just four amino acids (D-Arg-dimethylTyr-Lys-Phe-NH2). It was developed by researchers Hazel Szeto and Peter Schiller, which is where the “SS” name comes from. The Szeto-Schiller peptide family represents an entirely new class of compound: small molecules that selectively concentrate in the inner mitochondrial membrane and interact with its architecture directly.
Most nootropics and performance compounds work on receptors, neurotransmitters, or signaling cascades. SS-31 goes somewhere different — it goes inside the mitochondria and works on the physical structure of the membrane itself.
The Mechanism: Cardiolipin and the Energy Chain
To understand why SS-31 matters, you need to understand cardiolipin.
Cardiolipin is a phospholipid found almost exclusively on the inner mitochondrial membrane. It’s not just structural filler — it’s the scaffolding that holds the electron transport chain (ETC) together. The ETC is the series of protein complexes that actually produce ATP, your cellular energy currency. Without properly organized cardiolipin, those complexes don’t sit correctly in the membrane, their efficiency drops, and the whole system starts leaking electrons as reactive oxygen species (ROS) instead of capturing their energy as ATP.
As we age, cardiolipin degrades. Mitochondria become less tightly organized. The ETC gets less efficient. You produce more ROS and less ATP from the same substrates. This isn’t a minor inconvenience — it’s one of the central mechanisms behind age-related decline in muscle function, cardiac performance, cognitive sharpness, and metabolic health.
SS-31 binds directly to cardiolipin and stabilizes it. By restoring cardiolipin’s structural integrity, it allows the ETC complexes to reassemble and function properly. The result: more ATP produced per unit of substrate, less oxidative damage leaking out, and better mitochondrial architecture overall.
More recent research has also identified that SS-31 improves ADP sensitivity through the adenine nucleotide translocator (ANT) — meaning mitochondria become more responsive to energy demand signals, not just more efficient in steady state. That’s a meaningful distinction for athletes and anyone doing high-output work.
The FDA Approval — and Why It Matters Beyond Barth Syndrome
On September 19, 2025, the FDA granted accelerated approval for elamipretide (FORZINITY) to treat Barth syndrome — a rare, life-threatening genetic disease that primarily affects males and causes severe mitochondrial dysfunction, cardiomyopathy, and muscle weakness. Roughly 150 people in the US have it. Most have short lifespans.
This approval is historic for two reasons:
It’s the first treatment ever approved for Barth syndrome. Until now, there was nothing. Patients managed symptoms. Now there’s a drug that addresses the root mechanism — defective cardiolipin remodeling — directly.
It’s the first FDA-approved mitochondria-targeted therapeutic in history. Full stop. Decades of research into mitochondrial medicine finally produced a drug that made it through the regulatory process. That’s not just significant for Barth syndrome patients. It validates the entire mechanistic approach.
The approval didn’t come easily. The FDA advisory committee voted 10-6 in favor — a narrow margin. Earlier FDA staff reviews had questioned the effectiveness data. The path to approval was contested and prolonged. But it got there, and now FORZINITY is commercially available through AnovoRx Specialty Pharmacy.
What the Research Shows Beyond Barth Syndrome
Barth syndrome is the approved indication, but the clinical and preclinical research extends much further. This is what biohackers have been paying attention to for years:
Aging muscle. Studies in aged animals showed significant improvements in exercise tolerance, muscle strength, and mitochondrial efficiency after SS-31 treatment. The mechanism makes sense: aged muscle mitochondria have degraded cardiolipin, the ETC is less organized, and ATP production per unit of effort is lower. SS-31 partially restores the mitochondrial architecture that aging erodes.
Heart failure. SS-31 has been studied in human heart failure patients, with data showing improvements in cardiac mitochondrial function and some favorable secondary endpoints. The heart is the most metabolically demanding tissue in the body — it runs continuously at maximum output, making it particularly vulnerable to mitochondrial inefficiency.
Ischemia and reperfusion injury. One of SS-31’s most consistent signals across multiple tissue types is protection against ischemia-reperfusion injury — the cascade of damage that occurs when blood flow is restored after a period of restriction. Relevant for surgery, cardiac events, and potentially extreme training scenarios.
Kidney protection. Multiple studies have shown renal protective effects, particularly relevant for people at risk of kidney injury from contrast dye, ischemia, or metabolic disease.
Neuroprotection. Early evidence from animal models suggests protective effects on retinal cells and neurons under oxidative stress conditions. Given how metabolically active neural tissue is, this tracks mechanistically.
The big caveat: the large Phase III trials for heart failure — the CADUCEUS and PROGRESS trials — produced disappointing primary endpoint results, despite tantalizing secondary signals. Biohackers noticed the positive subgroup trends; regulators noticed the failed primary endpoints. “The story of SS-31 is a trip,” one longevity researcher put it. “Biohackers called it rocket fuel for a variety of indications, but placebo-controlled randomized trials told a different story tangled in patient variability.”
The lesson isn’t that SS-31 doesn’t work. It’s that proving efficacy across heterogeneous populations in complex conditions like heart failure is hard, and the approved indication — Barth syndrome, where cardiolipin defects are the primary and definitive pathology — is the clearest signal.
Why the Biohacking Community Got There First
The longevity and biohacking community started using gray-market SS-31 years before the FDA approval, and that pattern is worth understanding rather than dismissing.
The mechanistic logic was compelling from the beginning: mitochondrial dysfunction is a documented driver of aging, cardiolipin degradation is a documented driver of mitochondrial dysfunction, and SS-31 addresses cardiolipin directly. The animal data on aged tissue was promising. The safety profile across all trials was consistently clean — no serious adverse events attributable to the drug in healthy populations.
For people doing rigorous self-optimization — tracking biomarkers, running n-of-1 protocols, stacking compounds with clear mechanistic rationale — SS-31 fit the profile of something worth experimenting with long before it had regulatory backing.
The FDA approval doesn’t change the off-label math dramatically. It validates the mechanism and provides real human safety data in a clinical context, which is valuable. But for most biohackers, the question isn’t Barth syndrome — it’s whether SS-31 can meaningfully improve mitochondrial function in aging, healthy-but-declining tissue. That question doesn’t have a randomized controlled trial answer yet.
Administration and Practical Notes
SS-31 is administered subcutaneously — injected, not taken orally or intranasally. Peptides this small can survive some oral exposure, but subcutaneous delivery is how the clinical trials were run and how biohackers use it.
Based on community protocols and the clinical dosing landscape, typical self-experimentation doses run in the range of 5–10 mg daily, often with a higher loading phase of around 10 mg for the first several days. Some users cycle it; others run it continuously for defined periods.
The compound is water-soluble and relatively stable compared to many peptides. Injection site reactions are the most commonly reported side effect — mild and localized.
The practical challenge is sourcing. SS-31 is a more complex synthesis than simpler peptides, and quality varies across the research chemical market. The FDA approval of the pharmaceutical version doesn’t help much here — FORZINITY is an orphan drug with orphan drug pricing, distributed through a specialty pharmacy for a specific rare disease.
The Honest Limitations
The large heart failure trials not hitting primary endpoints is a real finding, not a footnote. It means the extrapolation from “this fixes cardiolipin in Barth syndrome” to “this reverses mitochondrial aging in everyone” hasn’t been clinically proven.
Long-term effects in healthy aging populations aren’t characterized. The safety record in trials is clean, but trial populations are monitored carefully and aren’t stacking SS-31 with other peptides, SARMs, and longevity compounds.
And the fundamental question — whether improving mitochondrial efficiency translates to meaningful performance or longevity gains in people who don’t have primary mitochondrial disease — remains genuinely open.
The Bottom Line
SS-31 just crossed a threshold that almost no compound in the longevity space ever reaches: FDA approval. That matters not because it means SS-31 works for everything biohackers hope it does, but because it confirms the mechanism is real, the safety profile is acceptable, and mitochondrial targeting is a pharmacologically viable strategy.
For people interested in the biology of energy, aging, and performance, the cardiolipin mechanism is among the most compelling targets in the space. You can argue about clinical trial design and patient population variability all day. What you can’t argue with is that the inner mitochondrial membrane degrades with age, cardiolipin is central to that process, and SS-31 is the only thing that’s ever been shown — and now approved — to address it directly.
Everything else in your longevity stack is working around the mitochondria. SS-31 goes inside.
This post is for informational purposes only and does not constitute medical advice. FORZINITY (elamipretide) is FDA-approved only for Barth syndrome. Off-label use of research-grade SS-31 is not medically supervised and occurs in a regulatory gray zone. Consult a healthcare professional before use.
